There's another nice price and volume surge on recent idea BOCX this morning off an early announcement. At the International Society of Oncology and Biomarkers being held this week in Amsterdam, BOCX is presenting a study that demonstrates their RECAF cancer marker, when used in conjunction with other tests for ovarian cancer and colorectal cancers, eliminated 100% of false positives.

This could be an early indication Biocurex plans to commercialize in combination with other tests along with it'sRECAF test on a stand alone basis.

This is very favorable data, and these early stage biotech ideas tend to trade on data of this kind.

As you can see, since coming off a multi month, low volume trip to the pricing cellar, BOCX has been pretty hot of late. We've made three trips to nearly $.30, and the quadruple move from $.05 to $.20 is holding in nicely. The stock is enjoying a decent volume day today off this news, having traded 350,000 shares 3 hours into the trading day.

A little more grinding around these levels sets us up to hold $.30, which is my short term target. If the company continues delivering results for the market, the stock is likely to run to its next level.